Screener
CytomX Therapeutics CTMX Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: CytomX Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337950
FAQ
- What is CytomX Therapeutics's accounts payable?
- CytomX Therapeutics (CTMX) reported accounts payable of $1.94M in Q2 2026.
- How has CytomX Therapeutics's accounts payable changed year-over-year?
- CytomX Therapeutics's accounts payable increased by 754.2% year-over-year, from $227K to $1.94M.
- What is the long-term trend for CytomX Therapeutics's accounts payable?
- Over 5 years (2020 to 2025), CytomX Therapeutics's accounts payable has grown at a -15.4% compound annual growth rate (CAGR), from $3M to $1.3M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about CytomX Therapeutics's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude